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Abstract A successful strategy in regenerative medicine 
over the last decade has been the translation of stem cell 
therapy to repair diseased or damaged tissue in a wide 
range of indications, despite limited evidence attributing 
any therapeutic benefit to cell survival or differentiation. 
Recent findings, however, have demonstrated that the 
conditioned media from stem cell cultures can produce 
similar efficacious effects compared to those observed for 
cells. This has led to the stem cell paracrine hypothesis, 
proposing that secreted factors released from the stem 
cells contribute significantly to their beneficial effects. It 
has been well documented that stem cells have the ability 
to release a range of growth factors, cytokines and 
chemokines relevant to their function; however, these 
factors are released at levels too low to account for the 
reported therapeutic effects. Further purification of the 
conditioned media has since identified that not only are 
small molecules released by the stem cells, but so too are 
a large quantity of membrane-bound vesicles, including 
exosomes, in a functionally relevant manner. In this 
review, we present our current understanding and 
explore the evidence supporting the development of stem 
cell-derived exosomes as a cell-free regenerative 
medicine.  
 





One major approach to regenerative medicine has been to 
replace lost tissue with new cellular material or facilitate 
the regeneration of damaged or diseased tissues by 
means of stem cell transplantation. Over the last two 
decades, therapeutic options have progressed from the 
grafting of whole tissue (such as bone marrow) to the 
injection of autologous or allogeneic stem cell products 
derived from adipose, blood, bone and brain tissue. More 
recently, pluripotent cells derived from embryonic stem 
(ES) cells or induced pluripotent stem (iPS) cells, using 
cellular reprogramming technologies, have been the 
source of new potential cell therapies. The translation of 
stem cell therapies from bench to clinic has been  
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remarkable, with thousands of trials currently registered 
in the National Institutes of Health clinical trials database 
(www.clinicaltrials.gov). The investigations span a broad 
range of indications, from microbial diseases, cancers and 
neoplasms, congenital, heart and blood disorders, 
nervous system diseases, immune disease (graft versus 
host, multiple sclerosis, arthritis and colitis), wounds and 
injuries. Results from the early phase trials have 
demonstrated cell therapy as safe, feasible and - in a 
number of indications - potentially efficacious, for 
example, in cardiology [1], ischaemic stroke [2], 
peripheral ischaemia [3] and cancer [4]. However, for 
many of these therapies, evidence of a therapeutic benefit 
cannot be attributed to stem cell survival and/or 
differentiation [5-7]. The beneficial effects of cell implants 
without long-term cell survival together with observed 
trophic effects of the cell-conditioned culture medium 
suggest that secreted paracrine factors may be involved 
[8, 9]. Small molecules (i.e., growth factors, chemokines 
and cytokines) are secreted at too low levels to account 
for the therapeutic efficacy reported [10]. However, the 
paracrine hypothesis has been strengthened by the recent 
discovery that stem cells release not only soluble factors 
but also extracellular vesicles which elicit similar 
biological activity to the stem cells themselves [11-14].   
 
The most prominent of the extracellular vesicles are 
exosomes. Exosomes have been shown to play a key role 
in cell-to-cell communication [15-20] and modulating 
cellular immunity [21-24]. Recent data suggest that 
exosomes may physically link beneficial outputs from 
stem cells to neighbouring diseased or injured cells 
through the delivery and transfer of protein, bio-active 
lipid and nucleic acid cargo, inducing phenotypic and 
functional changes in the recipient cells that promote the 
activation of regenerative programs [25-28]. The 
paracrine hypothesis has inspired an alternative approach 
in regenerative medicine: namely, translating the 
potential clinical applications based on exosomes secreted 
by the stem cells rather than the stem cells themselves, an 
approach underpinned by the discovery of the control 
system for the transport and delivery of cellular cargo for 
which E. Rothman, R.W. Schekman and T. C. Südhof
received the 2013 Nobel Prize for Medicine 
(www.nobelprize.org). 
 
2. Formation, release and function of exosomes 
 
Stem cell-derived exosomes have now been identified 
and isolated from cell culture supernatants of several 
cell types with known therapeutic potential, including 
mesenchymal stromal (MSC) [29-31], (bone marrow 
stem cells) mononuclear (MNC) [32], immune cells 
(dendritic and CD34+) [33, 34] and human neural stem 
cells (hNSCs) [35, 36]. Exosomes (30-100nm) can be 
distinguished from microvesicles (MVs) (100 nm-1μm) 
and apoptotic bodies (1- 5 μm) by size and morphology 
[37-39]. Exosomes are lipid bilayer-bound vesicles, 
released from cells after stimulation [40], and they 
express specific biomarkers independently of the cell 
source that will be detailed below. Unlike MVs, which 
are derived from plasma membrane shedding, exosomes 
are secreted by multivesicular bodies (MVBs) [38, 41-44]. 
Exosomes produced from a single cell can comprise a 
heterogeneous population of vesicles that may feature 
different markers, compositions and, potentially, 
different functions [40]. The heterogeneity of their 
composition, along with their stable physicochemical 
features, has led to the idea of using exosomes as 
natural nano-devices for the development of new 
therapeutic applications [45-48].  
 
Once released into the extracellular environment, 
exosomes may interact with recipient cells via adhesion 
to the cell surface mediated by lipid-ligand receptor 
interactions, internalization via endocytic uptake, or by 
direct fusion of the vesicles and cell membrane, which 
leads to the release of exosome content into the target cell 
[15, 49]. The net result of exosome-cell interactions is the 
modulation of the physiology of the target cell, induced 
through any of several different mechanisms, ultimately 
influencing the biology of tissue/the organism as a whole. 
The interactions involve many physiological processes, 
such as antigen presentation [50, 51], the transfer of RNA 
[28] and tissue repair [30]. Exosomes have been found to 
carry antigenic materials and express functional major 
histocompatibility (MHC) complexes, giving them the 
potential to mediate antigen-specific immune responses 
[52]. For example, tumour-derived exosomes captured by 
dendritic cells can induce the activation of antigen-
specific T-cells not previously exposed to the tumour 
antigen [21, 23], and the function of follicular dendritic 
cells has been attributed to membrane-bound exosomes 
containing MHC class II [53].  
 
Exosomes can also influence the biology of recipient cells 
via the delivery of bioactive content into target cells 
through the internalization of vesicles. The bilayer 
membrane encapsulation of exosomes provides a 
protected and controlled internal microenvironment, 
allowing cargo to travel long distances within tissues 
without degradation [27, 28, 54-56]. Most recent 
developments implicate a major role for the horizontal 
transfer of proteins and genetic materials (such as mRNA, 
microRNA (miRNA), pre-miRNAs, and other non-coding 
RNAs) in the reprogramming of recipient cells. ES cell-
derived exosomes have been demonstrated to 
shuttle/transfer mRNA and proteins to hematopoietic 
progenitors [26]. Other studies have shown that adult 
stem cell-derived exosomes also shuttle selected patterns 
of mRNA, miRNA and pre-miRNA associated with 
several cellular functions involved in the control of 
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transcription, proliferation and cell immune regulation 
[57-60].  
 
3. Exosomal features  
 
3.1 Membrane composition 
 
Besides their characteristic morphology, exosomes are 
unique in their bilayer membrane protein and lipid 
composition compared to other extracellular vesicles. 
Exosomal membrane components have been proposed as 
playing pivotal roles, such as signalling molecules in the 
uptake/fusion of exosomes with target cells and 
propagation of signalling in immune responses. For 
example, Rab GTPase membrane proteins have been 
implicated in membrane trafficking and secretion [61,62].  
3.2 Lipid rafts  
Lipid rafts are structurally and functionally unique 
microdomains in the cell membrane surface which 
function as sites for key membrane activities, such as 
endocytosis, cell adhesion and membrane trafficking [63]. 
Lipid rafts, tightly packed areas of sphingolipids and 
cholesterol compared to the surrounding areas, have been 
reported in both cellular and exosomal (including stem 
cell-derived) membranes [64]. As a consequence of the 
lipids’ composition and limited size, exosomes have a 
more rigid membrane than their parent cell [65]. High 
levels of ceramide (associated with biogenesis and 
release) have also been reported in exosomes [66]. Lipid 
rafts reflect the endosomal origin of exosomes and 
represent a distinctive feature, which may be useful for 
their differentiation and isolation from other secreted 
microparticles [65].  
 
3.3 Proteins  
 
Exosome membranes comprise both ubiquitous and cell 
type-specific proteins that cover numerous biological 
functions. A complete database of exosomal proteins can 
be found at ExoCarta (www.exocarta.org) [67]. Due to 
their endosomal origin, all exosomes contain membrane 
transport and fusion proteins (annexins, GTPases, 
flotillin), tetraspanins (CD9, CD63, CD81, CD82), heat 
shock proteins (Hsp70, Hsp90), proteins involved in 
multivesicle body biogenesis (Alix and TSG101), lipid-
related proteins and phospholipases [29,68]. These 
proteins have been associated with lipid rafts. Due to 
their size, lipid rafts can contain only a few proteins at 
one domain. To engage in a membrane function, lipid 
rafts cluster together and sequester specific sets of 
signalling and other proteins which serve as platforms to 
execute functions such as membrane trafficking and 
signalling [61].  
 
Proteins presented on the outer exoplasmic membrane 
layer are routinely used as identifying markers; however, 
there is wide variation in terms of protein profiles across 
exosomes from different cell sources. The most widely-
used markers are tetraspanins, Alix, flotillin, TSG101 and 
Rab5b, which are detected using antibody-based 
techniques (such as Western blot or ELISA) for the rapid 
confirmation of the presence of exosomes. 
 
3.4 Cargo contents 
 
Exosomal cargo can contain a variety of cytoplasmic 
nucleic acids, lipids and proteins, reflecting both the 
condition and origin of the parent or producer cell. As a 
result, exosomes exhibit some commonly shared contents 
and express distinctive molecules identifying their 
originating producer cell, but they also possess unique 
mixtures of proteins and RNA. The complexity of cargo 
contents has been postulated as a significant factor of 
exosomal efficacy in treating complex tissue injuries such 
as those that affect multiple tissues and targets [69]. 
Individual components in the cargo may not be equally 
or sufficiently efficacious, and the therapeutic efficacy of 
exosomes in relation to a specific injury may result from 
the synergy of a select permutation of individual 
exosome components. One aim of translational research is 
to assess the biochemical activities of these contents and 
identify the optimal permutations of these activities for 
therapeutic targets.  
 
There is a growing need for quick and easy methods for 
the analysis of exosomal cargo. The thorough molecular 
characterization of exosomes is hindered by the 
complexity of their composition, their high heterogeneity 
and their low abundance. To date, only a few studies 
have been conducted that have provided a systematic 
characterization of the protein and the genetic 
composition of stem cell-derived exosomes [29, 35, 57, 58, 
69-71] (Table 1). 
 
A number of proteins have been identified in the functional 
cargo of stem cell-derived exosomes which affect a variety 
of cellular functions [14, 18, 26, 49, 72, 73]. Recent 
developments in protein separation techniques, 
spectrometry, immunological methods and bioinformatics 
have enabled the systematic characterization of MSC-
derived exosomes [29, 68, 69] (Table 1). These analyses 
have identified over 700 proteins that reflect: (1) the 
evolutionary conserved set of exosomal proteins (CD81, 
CD63, CD9 [tetraspanins], Alix, Tsg101) and those tissue 
or cell type-specific proteins; (2) integration of parental 
cellular processes and genes of self-renewal and 
differentiation; and (3) a list of proteins that can be 
associated with therapeutic potential [29].  
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Functional Group / 
Component   
Constituent Type (description) Exosome Source / Reference
Surface receptors Platelet-derived growth factor receptor beta (PDGF-Rβ) 
Epidermal growth factor receptor (EGFR) 




R-Ras / N-RAS 
Mitogen-activated protein kinase 1(MAPK1) 
Guanine nucleotide binding protein 13 (GNA13) 
Guanine nucleotide binding protein (G protein), gamma 12 (GNG12) 
Cell division cycle 42 (CDC42) 
Guanine nucleotide exchange factor (VAV2) 
hBM-MSC [29] 
Ras-related Rab proteins 
Laminin-R 
14-3-3 proteins  
hBM-MSC [29] 
Cell adhesion Fibronectin 1 (FN1) 




Lectin, galactose binding, soluble 1 (LGALS1) 
Lectin, galactoside-binding, soluble, 3 (LGALS3) 
hBM-MSC [29] 
CD34 hCD34+ and MNC[34] 
MSC-associated 
antigens  
CD63 hBM-MSC [29]; hCD34+  and 
MNC [34]  
CD109, CD151 hBM-MSC [29] 
CD248, and CD276 hBM-MSC [29] 
CD13, CD73, CD105 hBM-MSC [29] 
CD29, CD44, CD73, CD90, and 
CD105 positivity (MSC markers) 
hBM-MSC[29] 
CD9, CD81 hBM-MSC[29], hCD34+ and 
MNC [34]; hESC-MSC [64] 
Raft-associated 
proteins  
Transluminal protein (TSG101)  hCD34+ and MNC [34];  
hESC-MSC [64] 
Annexin V (bound to Phosphatidylserine)    hCD34+ and MNC [34] 
Alix / actin interacting protein 1 (AIP1)  hESC-MSC [30, 64, 104] 











Phosphatidylserine hCD34+ and MNC[36] 
Novel protein cargo Prostaglandin G/H synthase (cell proliferation) 
Cathepsin F precursor (intracellular degradation and turnover of proteins) 
Sarcoma antigen 1 (tumour marker) 
Polymyositis/scleroderma (autoantigen to nuclear proteins) 
hNSC [35] 





MiRNA126 and MiRNA 130a (angiogenesis) hCD34+ and MNC [34] 
MiRNA133b (stroke recovery) Mouse MSC [104, 111] 
MiRNA 96, miRNA124 and miRNA199a (differentiation) hBM- MSC[115] 
MiRNA 451 (maintenance, differentiation)  
MiRNA 223 (regulator of cell cycle)  
hBM-MSC and HLSC [58]  
 
MiRNA 335 (markers of cell of origin for BM-derived MSCs) 
MiRNA 564 (selective expression in MSC exosomes compared to MSCs) 
hBM-MSC[58] 
MiRNA 142-3p, miRNA 501 (selective expression in HLSC exosomes 
compared to HLSCs) 
HLSC[58] 
Abbreviations: BM, Bone marrow; hESC, human embryonic stem cells; hNSC, human neural stem cells; HLSC, human liver resident 
stem cells; hMSC, human mesenchymal stem cell; MI, Myocardial infarction; miRNA, micro-RNA; MNC, mononuclear cells 
Table 1. Examples of functional components isolated from stem cell-derived exosomes  
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4. Proteomic characterization  
 
Techniques such as Shotgun proteomic analysis of the 
peptide mixtures from exosomal fractions have been used 
to identify proteins from hNSCs [35]. A total of 103 
proteins were detected in a sample of hNSC-derived 
exosomes, including previously reported heat shock 70 
kDa, transferrin receptor, HLA DR4 and ezrin, and 
several as yet unreported such as anhydrolase-domain-
containing-8, G protein-coupled receptor associated 
sorting protein 1, the 70 kDa heat shock protein 1A 
variant, and prostaglandin G/H synthase. Rarer proteins 
such as cathepsin F precursor and sarcoma antigen 1 
which were also detected were uniquely present in only 
one fraction (Table 1).  
 
5. Genetic information in stem cell–derived exosomes  
 
Mitochondrial DNA, mRNA and non-coding RNAs such 
as miRNA have been reported in stem cell-derived 
exosomes and may deliver horizontal gene transfer to 
target cells [11, 74, 75]. Exosomes derived from human 
stem cells have been shown in vivo to deliver human 
mRNA to mouse cells, resulting in protein translation [76, 
77]. Exosomes derived from ES cells contain abundant 
miRNA and have been demonstrated to transfer a subset 
of miRNAs to mouse embryonic fibroblasts in vitro [60].  
 
MiRNA is a class of small, non-coding RNA molecules 
consisting of 19 to 24 nucleotides that have a variety of 
cellular properties associated with both physiological and 
pathological processes. They are involved in homeostasis, 
the post-translational modification of gene expression, 
oncogenesis and tumour suppression, RNA and protein 
complex shuttling, and protection from RNase enzymatic 
degradation [20, 78-83]. Exosomes provide a protected 
and controlled internal microenvironment, allowing 
miRNA molecules to travel long distances within tissues 
without degradation [54]. Evidence suggests that miRNA 
packaging occurs non-randomly and that specific miRNA 
populations are preferentially sorted and shuttled into 
MVs [84], and secreted contents could vary in response to 
different stimuli [58]. Important questions, regarding how 
miRNAs are sorted into exosomes (shedding vesicles and 
high density lipoprotein (HDL) particles), whether there 
is regulated specificity in this process, how secreted 
vesicles are taken up by recipient cells and whether 
specific cells are targeted, need to be addressed.  
 
The transfer of human mRNA via exosomes and its 
translation into protein have been observed both in vitro 
and in vivo in diverse experimental models [28]. RNA 
inactivation resulted in the significant loss of biological 
activities, suggesting that the transfer of nucleic acids has 
a relevant role [85]. However, exosomes also transfer 
regulators of transcription as they induce changes in the 
gene expression of the recipient cells, such as the up-
regulation of the BCL family genes and the down-
regulation of CASP1 (caspase 1), CASP8 (caspase 8) and 
LTA (lymphotoxin α) genes involved in the “execution” 
phase of cell apoptosis [80]. 
 
Moreover, the miRNAs present in exosomes are 
candidates for the post-transcriptional regulation and 
induction of epigenetic changes in the recipient cells. 
miRNAs shuttled by EPC-derived MVs are the main 
effectors of the pro-angiogenic and renoprotective 
activities of MVs [79]. In fact, the non-specific as well as 
the specific depletion of miRNAs in MVs obtained from 
Dicer- or miRNA126- and miRNA-296-knockdown EPCs 
modify their biological effects [79, 86]. 
 
The number of secreted miRNAs identified in stem cell-
derived exosomes has been expanding (Table 1) and their 
role and biological/physiological significance is of 
considerable interest. Stem cell types and their derived 
exosomes have distinct miRNA profiles [34, 86, 87], and 
are listed in http://exocarta.org/mirna and 
http://www.mirbase.org.  
 
5.1 Producer cells 
 
To ensure the large scale supply required for clinical 
research and development, producer cell immortalization 
(either by natural selection or by genetic modification) 
and clonal isolation is a practical strategy to produce 
functionally bioactive exosomes for use as therapeutic 
agents or delivery vehicles [47, 88, 89]. Immortalization 
ensures production stability and reduces the equivalence 
testing of new production lots. Bioreactors and other 
specialized culture systems are also used for culture 
expansion and to increase the yields of exosomes and 
MVs [88, 90]. In respect of genetically modified producer 
cells, the immortalizing oncogene (e.g., c-myc) and its 
protein product are not trafficked into the exosomes [88]. 
 
While secreted exosomes from a range of cell types 
exhibit some common shared contents, they also express 
molecules that reflect their cells of origin [44, 58, 71] and 
their microenvironment (e.g., culture conditions) [37, 91-
93].  
 
Exosomes are released from producer cells with stable 
phenotypes. The possibility of changing the phenotype of 
the exosomes represents a novel therapeutic strategy for 
cell-free regenerative medicine. Pre-treating the producer 
cells with different cytokine cocktails, etc., to drive a 
specific response [94], or stimulating/exposing producer 
cells - in effect mimicking cells’ responses to a local 
diseased/damaged environment after implantation - can 
result in exosomes therapeutically suited to specific 
indication, as in cancer vaccines [95].  
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5.2 Preparation, isolation and manufacture of stem cell-derived 
exosomes  
 
Efforts to harvest purified exosomes in clinically 
significant quantities are limited by the lack of tools and 
methods to differentiate them from microparticles in 
general and isolate different subsets. Most cell types 
produce exosomes; those produced by cultured cells are 
isolated from the conditioned media (Figure 1). 
Additionally, the yield from different cell types varies 
significantly. Within MSCs, for example, the production 
of exosomes from ES cell-derived MSCs is up to seven-
times that from cord blood- or bone marrow-derived 
MSCs, suggesting a direct correlation between the donor 
cell ‘immaturity’ and exosome yield [96].  
 






As yet, there is no agreed or standardized method for the 
preparation and purification of exosomes from cell-
conditioned culture media (Table 2). MVs, exosomes, 
debris and culture media contaminants are all contained 
in the conditioned medium. Serum-free defined media 
may be used to reduce contamination with a serum or its 
components. Also, it is difficult to analytically distinguish 
exosomes from other membrane vesicles due to the 
limitations of commonly-used separation procedures, 
namely ultracentrifugation and flow cytometry [97]. The 
overall size of exosomes (<100 nm) has been an important 
criterion for distinguishing them from the other larger 
membrane-bound microvesicle secretions. Among 
current methods (differential centrifugation, 
discontinuous density gradients, immunoaffinity, 
ultrafiltration and high performance liquid 
chromatography (HPLC), differential centrifugation is the 
most commonly used for exosome isolation, which 
utilizes an increasing centrifugal force from 2000xg to 
10,000xg to separate the medium- and larger-sized 
particles and cell debris from the exosome pellet at 
100,000xg [33, 98-100]. Although crude and non-specific, 
this method has been reported to allow for the significant 
separation/collection of exosomes from a conditioned 
medium. However, protein aggregates, genetic materials, 
particulates from media and cell debris are common 
contaminants. To enhance the specificity of exosome 
purification, sequential centrifugation has been combined 
with ultrafiltration [98], or equilibrium density gradient 
centrifugation in a sucrose density gradient or Optiprep®, 
to provide for the greater purity of the exosome 
preparation (flotation density 1.1-1.2g/ml) [99] or sugar 
cushion [29, 33, 101].  
 
The isolation of exosomes based on size is another option. 
Ultrafiltration can be used to purify exosomes without 
compromising biological activity. Membranes with 
different pore sizes - such as 100 kDa molecular weight 
cut-off (MWCO) and gel filtration to eliminate smaller 
particles - have been used to avoid the use of a non-
neutral pH or non-physiological salt concentration [33, 
100]. Currently available tangential flow filtration (TFF) 
systems are scalable (to >10,000L), purify and concentrate 
the exosome fractions [29] (www.pall.com), and are less 
time consuming than differential centrifugation. HPLC 
can also be used to purify exosomes to homogeneously-
sized particles and preserve their biological activity as the 
preparation is maintained at a physiological pH and salt 
concentration [68, 88]. Although the purity of the 
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Isolation Method Indicator of Exosome Sample 
Purity for Clinical Use  
Advantages Disadvantages  
Differential 
centrifugation [22, 33, 98]  
Ratio of total MHC class II 
molecules per mg total protein (1-
2% of total protein being MHC II 
class); absence of non-exosomal 
proteins, haptoglobin and  human 
serum albumin (<1-2% of overall) 
using SDS-PAGE and ELISA; low 
levels of DNA (<50ng/ml) [33] 
Potential for sterile 
preparations [33, 98] 
Time consuming; low recovery, 
poor reproducibility due to 
operator variability [33] 
Pellet re-suspension difficult [99] 
Contamination with other 
microparticles of overlapping size 
distribution, protein aggregates, 
particulates from media and cell 
debris [33, 100, 101] 
Ultrafiltration (500 kDa 
MWCO hollow fibre) + 
centrifugation using 
sucrose –D20) density 
cushion (1.21g/cm3) [33] 
Ratio of total MHC class II 
molecules per mg total protein (1-
2% of total protein being MHC II 
class); absence of non-exosomal 
proteins, haptoglobin and human 
serum albumin (<1-2% of overall) 
using SDS-PAGE and ELISA; low 
levels of DNA (<50 ng/ml) [33] 
Potentially high enrichment of 
exosomes; useful for clinical 
applications [33]  
Hollow fibre cartridge removed 
dead cells and debris by using 
membranes with different pore 
sizes (i.e., 100kDa MWCO) 
The protein content of samples 
remained consistent [33] 
Sterile preparations  
Less time consuming than 
ultracentrifugation [100] 
Filtration reduced scalability of 
the subsequent centrifugation 
method [99] 
Ultrafiltration 100 kDa 
MWCO membrane 
(Minimate TFF capsule 
system, PALL 
Corporation, Ann Arbor, 
MI) and sequential 
ultracentrifugation onto 
a sucrose gradient [29] 
Protein concentration 
(refractometry and Bradford dye 
assay) of final exosomal 
preparation [29] 
 




HPLC + centrifugation 
[30, 88] 
  
Presence of CD9 (western blot) 
and homogenous in size (DLS), 
flotation density 1.11-1.16 g/ml, 
proteins MW range from 20 to 250 
kDa [30] 
1.5 mg of exosomes from 1L of 
conditioned medium; doses of 0.3 
or 0.4 μg per mouse [88] 
High throughput 
High purity (homogeneous 
sized particles) 
Biological activity preserved 
as preparation is maintained 
at physiological pH and salt 
concentration [99] 
Low yields 
Expensive equipment  and poor 




using sugar cushion 
(30% sucrose/D2O 
cushion for I hour) [101] 
Expressed as ratio of particle to 
protein  high purity at 3.3 x1010 
P/μg; impure if <1.5 x 109 P/μg 
[101] 
 
Sugar cushion resulted in high 
purity and greater elimination of 
non-vesicular proteins [101] 
Useful for high through put and 
clinical preparations[101] 
Applicable for purification of  
large amounts of exosomes  
Affinity beads [98, 102] 
 
Not determined  Easy to use with fewer steps 
than centrifugation methods  
High specificity, dependent on 
choice of marker for 
immobilization [98]  
Selection of exosome population 
subset; not intended for 
purification of large amounts of 
exosomes [98]   
Difficulty in completely 
removing antibodies from 
sample and eluting fully 




Number of particles within size 
range detected NanoSight 
tracking system [100]   
Potentially high yields  
Fewer steps than 
centrifugation methods 
No method for removing 
polymers from exosome sample  
Pellet difficult to re-suspend [100] 
Flow field-flow 
fractionation (FlFFF)[35]  
Not determined  Analytical technique for 
fractionation of exosomes, 
useful for morphological and 
protein characterization  
Not for large-scale preparation 
of exosomes 
Abbreviations:  Dynamic light scattering (DLS); Flow field-flow fractionation (FlFFF); high pressure liquid chromatography (HPLC); 
kiloDalton (kDa); molecular weight cut off (NMWCO); tangential flow filtration (TFF) 
Table 2. Exosome isolation methods from cell culture media 
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Immunoaffinity is a highly scalable technique using 
antibodies recognizing exosome-associated antigens 
conjugated to magnetic beads, chromatography matrices, 
plates or microfluidic devices [67, 88, 98, 102]. The 
antibodies can be used by themselves or in combination. 
For example, ExoTest® kits feature anti-CD63, -CD81 or -
CD9 antibodies immobilized on 96 well plates for 
exosome capture and characterization 
(www.HansaBioMed.eu). Other affinity-capture methods 
use lectins which bind to specific saccharide residues on 
the exosome surface (www.AethlonMedical.com). The 
targets or markers for affinity capture need to be 
identified to optimize the high specificity offered by this 
technique.  
 
Exosomes can also be purified by using differential 
solubility in volume-excluding polymers, such as 
polyethylene glycols (PEGs) and low-speed centrifugation 
or filtration. Based on this concept, System Biosciences has 
released a proprietary reagent called ExoQuick® that can be 
added to the conditioned cell media to precipitate the 
exosomes (www.SystemBio.com). The procedure has been 
reported as being fast and straightforward. However, it is 
not specific for exosomes and pellet re-suspension is 
difficult [100].  
 
Flow field-flow fractionation (FlFFF) is an elution-based 
technique that is used to separate and characterize 
macromolecules (e.g., proteins) and nano- to micro-sized 
particles (e.g., organelles and cells) and which has been 
successfully applied to fractionate exosomes from hNSCs 
culture media [35].  
 
Defining the purity of an exosomal preparation is critical 
to defining the product prior to any translational 
development [101]. The production of clinical-grade 
exosome products would require current Good 
Manufacturing Practice (cGMP). Exosomal products are 
more stable and easier to store and transport to the 
clinical site than stem cells [47]. The use of clinical-grade 
immortalized stem cell lines can reduce the time required 
for cell production, allowing cell banking and scalability, 
and thereby reducing production costs, and can also be of 
value in a strategy for GMP manufacturing [68, 88]. Also 
essential for the development of exosomes products are 
release assays, required for establishing the storage, shelf 
life and stability of the exosome products prior to clinical 
trials [46, 103].  
 
6. Developing a stem cell-derived exosome product  
 
6.1 Therapeutics  
 
For clinical translation to be realized, it is necessary to 
characterize the physiochemical properties/phenotype of 
the purified exosome population along with the content 
and/or cargo of these vesicles in terms of proteins and 
small RNAs (Table 1). By addressing in an unbiased 
manner the genomic and proteomic content of the 
purified exosomes, it may be possible to predict the 
cellular targets and pathways that may be influenced.  
 
Therapeutic approaches based on the delivery of miRNAs 
are currently being explored for cerebrovascular, 
myocardial and peripheral ischaemia. MSC-derived 
exosomes have been found to increase the miRNA-133b 
level when exposed to middle cerebral artery occlusion 
(MCAo) brain extracts [104]. MiRNA-133b is substantially 
down-regulated in the rat brain after MCAo. The 
therapeutic approach is to increase miRNA-133b in the 
brain tissue via exosomes to stimulate neurite outgrowth 
and improve functional recovery after stroke. Similarly, 
MSC-derived exosomes were also able to provide 
protection against myocardial ischaemia and treat 
myocardial infarction through the expression of higher 
levels of precursor forms of hsa-let-7b and hsa-let-7g 
miRNAs. CD34+ stem cell-derived exosomes are 
described as inducing angiogenic activity in isolated 
endothelial cells and in murine models of vessel growth. 
The benefit of CD34+ cell therapy for functional recovery 
after ischaemic injury could be induced by the exosome-
mediated transfer of angiogenic factors to surrounding 
cells. Preliminary data on the mechanism that may 
mediate the enhanced potency of CD34+-derived 
exosomes have shown that the pro-angiogenic miRNAs 
126 and 130a were highly expressed in CD34+ exosomes 
compared with other unselected MNCs [34].  
 
In another study, protein profiling led to the 
identification of 20S proteasome using the ExoCarta 
database as a candidate exosome protein, with the 
therapeutic potential to ameliorate tissue damage after 
myocardial infarction [69]. Exosomes - as active 
components of conditioned medium from human ES cell-
derived MSCs - injected into swine and murine models of 
ischaemia /reperfusion injury reduced the infarct size 
[30]; from bone marrow-derived MSCs, they accelerated 
repair in mouse models of acute kidney injury [77]; and 
from liver-derived stem cells, they induced proliferation 
and apoptosis resistance in cultured human hepatocytes 
[76]. Many more detailed functional studies are required 
to discover other candidate proteins and their therapeutic 
potential.  
 
6.2 Clinical experience  
 
Only one stem cell-derived exosome product has been 
used clinically to date [105]. In this first attempt, the 
administration of escalating doses of exosomes derived 
from donor bone marrow MSCs into a patient suffering 
from severe therapy-refractory cutaneous and intestinal 
graft-versus-host disease grade IV was found to be well 
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tolerated and led to a significant and sustainable decrease 
of symptoms. A small number of clinical trials are 
currently investigating dendritic cell-derived exosomes 
for immunotherapy or vaccination in severe cancers, such 
as non-small lung (Phase II, NCT01159288) [106], glioma 
(Phase I NCT01550523) [107] and gastric (Observational, 
NCT01779583), and with Phase I trials in non-small lung 
small lung ([108], colorectal [109] and melanoma [110] 
completed. Interestingly, the use of plant-derived 
exosomes as vehicles to deliver curcumin to treat colon 
cancer is also under scrutiny (Phase I, NCT01294070).  
 
6.3 Advantages/limitations of exosome therapeutics 
 
The research to date indicates that stem cell-derived 
exosomes potentially have significant clinical utility. 
Exosome-based, cell-free therapies - in contrast to cell-
based therapies in regenerative medicine - can be 
generally easier to manufacture and prima facie safer, as 
they are non-viable and will not form tumours. By 
replacing the administration of live cells with their 
secreted exosomes, many of the safety concerns and 
limitations associated with the transplantation of viable 
replicating cells could be mitigated.  
 
Stem cell-derived exosomes have generally been found to 
be less immunogenic than parental cells, as a result of a 
lower content of membrane-bound proteins, such as 
MHC complex molecules [10]. Thus, ‘off-the-shelf’ 
products may be readily developed using exosomes with 
negligible alloimmunogenicity.  
 
Cell-free products offer a number of advantages 
compared to cell transplantation. Exosomes – in a manner 
similar to conventional biopharmacological products - 
can be standardized and tested in terms of dose and 
biological activity. Exosomes can be stored without 
potentially toxic cryopreservatives at -20°C for six months 
with no loss to their biochemical activity [100]. 
 
An important feature of exosomes is the encapsulation 
and protection of their contents from degradation in vivo, 
thereby potentially preventing some of the problems 
associated with small soluble molecules such as 
cytokines, growth factors, transcription factors and 
RNAs, which are rapidly degraded [28].  
 
The durability of exosomes in culture allows for the 
acquisition of large quantities of exosomes through their 
collection from a culture medium in which the exosomes 
are secreted over periods of time. 
 
Scalable systems for exosome production to support 
large-scale commercially viable manufacturing processes 
need to be developed.  
While exosomes exhibit several attractive features as a 
therapeutic agent, there are also potential limitations to 
be considered as well. Exosomes contain a mixture of 
biologically active molecules, some of which seem to have 
beneficial effects, whereas others might have detrimental 
(e.g., proinflammatory) effects under certain conditions. 
Whether exosomes will turn out to be superior to 
angiogenic drugs or purified recombinant growth factors 
and other peptides within the context of cell-free 
approaches to tissue regeneration remains to be seen.      
 
In addition, these naturally-occurring secreted membrane 
vesicles are better tolerated in the body, as evidenced by 
their ubiquitous presence in biological fluids, and have an 
intrinsic homing ability. In contrast to cell-based therapy, 
stem cell-derived exosomes provide an ‘off-the-shelf’ 
therapeutic product and will incur less manufacturing 
and storage costs. 
 
Similarly, most stem cells can be readily genetically 
modified, either by integrating viruses or episomal 
transfection. It is known that the overexpression or 
knock-down of miRNAs can result in similar over- or 
under-expression in exosomal cargo [79, 104, 111-113]. 
This has been exploited in preclinical studies where 
genetically modified exosomes have shown relevant 
therapeutic outcomes [78, 104, 111-114].   
 
6.4 Clinical and regulatory considerations 
 
While the application of stem cell-derived exosomes 
remains largely untested by regulatory authorities in 
advance of clinical trials, it is likely that these products 
will be seen in a similar way to their parent cells.  
 
Safety testing will focus on systemic bio-distribution, 
toxicity/tolerability and half-life studies. Compared to 
stem cell therapy, exosomal products can be delivered 
more readily by less sophisticated and more conventional 
delivery devices as the formulation and stability will be 
similar to biologics. Repeat administration and even self-
administration may also be possible in the future due to 
more straightforward product presentation. In addition, 
the much lower cost of such goods will be attractive to 
healthcare funders. 
 
7. Future scope    
 
The number of peer-reviewed publications focusing on 
exosomes has increased exponentially over the past 
decade. The newly founded International Society for 
Extracellular Vesicles (ISEV) is seeing a rapid rise in the 
number of presentations on the therapeutic use of 
exosomes. Much excitement and promise has been 
generated around the use of exosomes in cell-free 
regenerative medicine, which offers the potential for 
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safer, low risk products to cover a wider range of 
applications. Databases such as ExoCarta have facilitated 
the sharing of data regarding the genomics and 
proteomics of exosomes. As this data continues to accrue, 
it will become important to determine which factors are 
most relevant to exosome functions. Also key to exosome 
product translation will be advances in GMP supply and 
the production of clinical grade products, product 
characterization and potency assays, preclinical proof of 
efficacy and the identification of target populations. 
Although some exosomal preparations are already being 
administered in the clinic, the regulatory road map for 
stem cell-derived exosome product translation to clinical 
application will need to be established soon so as to keep 
pace with research demands.  
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